{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-114304","form_type":"8-K","ticker":"RYTM","cik":"0001649904","company_name":"RHYTHM PHARMACEUTICALS, INC.","filed_at":"2024-11-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.105213+00:00","generated_at":"2026-05-30T05:23:13.842710+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Rhythm Pharma Q3 revenue $33.3M (+14% seq); FDA Priority Review for label expansion to age 2","bullets":["IMCIVREE net revenue $33.3M (Q3 2024), up 48% YoY from $22.5M; US sales $23.3M (+8% seq), ex-US $10.0M (+35% seq).","Net loss $(45.0)M ($(0.73)/share) vs $(44.2)M ($(0.76)/share) in Q3 2023; cash $298.4M at Sep 30, 2024.","FDA accepted sNDA for Priority Review to treat children as young as 2 years; PDUFA date Dec 26, 2024.","Phase 3 hypothalamic obesity trial top-line data on track for 1H 2025; early-access French data showed 12.8% BMI reduction at 3 months.","FY 2024 non-GAAP operating expense guidance narrowed to $245-255M from $250-270M."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-114304","json":"https://secwatch.observer/filing/0001104659-24-114304.json","markdown":"https://secwatch.observer/filing/0001104659-24-114304.md","text":"https://secwatch.observer/filing/0001104659-24-114304.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1649904/000110465924114304/0001104659-24-114304-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1649904/000110465924114304/tm2427018d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T05:23:13.842710+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}